October 2025
1. WANG S, Liang K, Hu Q, Li P, et al
   Expression of Concern for JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
   J Clin Invest. 2025;135:e200302.
   

   >> Share

   
   September 2025
2. KUMARI N, Wright SC, Witham CM, Monserrat L, et al
   USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.
   J Clin Invest. 2025 Sep 23:e180927. doi: 10.1172/JCI180927.
   

   >> Share

   
   
3. SCHOLTEN D, El-Shennawy L, Jia Y, Zhang Y, et al
   Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis.
   J Clin Invest. 2025;135:e193521.
   

   >> Share

   
   August 2025
4. KIM S, Son E, Park HR, Kim M, et al
   Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models.
   J Clin Invest. 2025 Aug 12:e188839. doi: 10.1172/JCI188839.
   

   >> Share

   
   
5. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
   Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
   J Clin Invest. 2025;135:e196478.
   

   >> Share

   
   July 2025
6. ZHANG G, Jurinovic V, Bartels S, Christgen M, et al
   A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-responders.
   J Clin Invest. 2025 Jul 24:e177813. doi: 10.1172/JCI177813.
   

   >> Share

   
   
7. YANG Y, Chen C, Lyu Y, Gololobova O, et al
   HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin beta3-containing extracellular vesicles.
   J Clin Invest. 2025;135:e190470.
   

   >> Share

   
   
8. KALFEIST L, Ledys F, Petit S, Poirrier C, et al
   Co-targeting TGF-beta and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.
   J Clin Invest. 2025;135:e184422.
   

   >> Share

   
   
9. SURESH S, Ford JM
   A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer.
   J Clin Invest. 2025;135:e193171.
   

   >> Share

   
   
10. ZENG X, Zhao F, Tu X, Zhang Y, et al
    Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.
    J Clin Invest. 2025;135:e188120.
    

    >> Share

    
    June 2025
11. BOSE M, Singh MI, Frodin M, Ejlertsen B, et al
    Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects.
    J Clin Invest. 2025;135:e181879.
    

    >> Share

    
    
12. THATTE J, Moises da Silva A, Borcsok J, Gudjonsson T, et al
    The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.
    J Clin Invest. 2025;135:e188165.
    

    >> Share

    
    May 2025
13. CHEN MK, Yamaguchi H, Gao Y, Xia W, et al
    FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models.
    J Clin Invest. 2025 May 29:e173757. doi: 10.1172/JCI173757.
    

    >> Share

    
    April 2025
14. YANG SY, Jin ML, Andriani L, Zhao Q, et al
    Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer.
    J Clin Invest. 2025 Apr 29:e183531. doi: 10.1172/JCI183531.
    

    >> Share

    
    January 2025
15. SAFAEE TALKHONCHEH M, Sjolund J, Bolivar P, Kurzejamska E, et al
    An Activin Receptor-Like Kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases.
    J Clin Invest. 2025 Jan 14:e183086. doi: 10.1172/JCI183086.
    

    >> Share

    
    November 2024
16. CAI Y, Liu CC, Zhang Y, Liu Y, et al
    MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.
    J Clin Invest. 2024 Nov 12:e183656. doi: 10.1172/JCI183656.
    

    >> Share

    
    
17. WU S, Zheng Y, Olopade OI
    The convergence of genomic medicine and translational omics in transforming breast cancer patient care.
    J Clin Invest. 2024;134:e187520.
    

    >> Share

    
    October 2024
18. SINHA S, Callow BW, Farfel AP, Roy S, et al
    Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
    J Clin Invest. 2024;134:e170953.
    

    >> Share

    
    
19. KUMAR A, Goel H, Wisniewski C, Wang T, et al
    Neuropilin-2 expressing cells in breast cancer are S-nitrosylation hubs that mitigate radiation-induced oxidative stress.
    J Clin Invest. 2024 Oct 1:e181368. doi: 10.1172/JCI181368.
    

    >> Share

    
    September 2024
20. WINKLER J, Tan W, Diadhiou CM, McGinnis CS, et al
    Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.
    J Clin Invest. 2024;134:e164227.
    

    >> Share

    
    
21. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    

    >> Share

    
    August 2024
22. SHEN Y, Yan J, Li L, Sun H, et al
    LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis.
    J Clin Invest. 2024;134:e177357.
    

    >> Share

    
    May 2024
23. MARCHESE E, Demehri S
    Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    J Clin Invest. 2024;134:e180914.
    

    >> Share

    
    April 2024
24. JOHNSON N
    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    

    >> Share

    
    March 2024
25. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    J Clin Invest. 2024;134:e176390.
    

    >> Share

    
    January 2024
26. LUO M, Bao L, Xue Y, Zhu M, et al
    ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
    J Clin Invest. 2024;134:e171166.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share